MX2024004077A - Ligandos de proteina de activacion de fibroblastos radioetiquetados. - Google Patents
Ligandos de proteina de activacion de fibroblastos radioetiquetados.Info
- Publication number
- MX2024004077A MX2024004077A MX2024004077A MX2024004077A MX2024004077A MX 2024004077 A MX2024004077 A MX 2024004077A MX 2024004077 A MX2024004077 A MX 2024004077A MX 2024004077 A MX2024004077 A MX 2024004077A MX 2024004077 A MX2024004077 A MX 2024004077A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- activation protein
- fibroblast activation
- radiolabelled
- fap
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 3
- 230000004913 activation Effects 0.000 title abstract 2
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229910052765 Lutetium Inorganic materials 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052733 gallium Inorganic materials 0.000 abstract 1
- 229910052738 indium Inorganic materials 0.000 abstract 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002285 radioactive effect Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/06—Aluminium compounds
- C07F5/069—Aluminium compounds without C-aluminium linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21200719 | 2021-10-04 | ||
| EP22151771 | 2022-01-17 | ||
| PCT/EP2022/077598 WO2023057457A1 (en) | 2021-10-04 | 2022-10-04 | Radiolabelled fibroblast activation protein ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004077A true MX2024004077A (es) | 2024-04-18 |
Family
ID=84330437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004077A MX2024004077A (es) | 2021-10-04 | 2022-10-04 | Ligandos de proteina de activacion de fibroblastos radioetiquetados. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4412996A1 (enExample) |
| JP (1) | JP2024536362A (enExample) |
| KR (1) | KR20240093543A (enExample) |
| AU (1) | AU2022358921A1 (enExample) |
| CA (1) | CA3234394A1 (enExample) |
| IL (1) | IL311694A (enExample) |
| MX (1) | MX2024004077A (enExample) |
| WO (1) | WO2023057457A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白（ｆａｐ）抑制劑、ｆａｐ結合物及其診斷與治療用途 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| CN120957982A (zh) | 2023-05-08 | 2025-11-14 | 江苏恒瑞医药股份有限公司 | 靶向成纤维细胞活化蛋白的配体 |
| CN116925041B (zh) * | 2023-06-12 | 2024-12-24 | 上海交通大学医学院附属仁济医院 | 靶向成纤维细胞激活蛋白的氟标记放射性药物前体、放射性标记化合物及其应用 |
| CN120136958A (zh) * | 2023-12-13 | 2025-06-13 | 无锡诺宇医药科技有限公司 | Fap靶向放射性药物 |
| WO2025167951A1 (zh) * | 2024-02-07 | 2025-08-14 | 苏州博锐创合医药有限公司 | 一种成纤维细胞活化蛋白抑制剂 |
| TW202600606A (zh) * | 2024-02-21 | 2026-01-01 | 美商雅博得樂醫療公司 | 抗體連接子結合物 |
| CN122319156A (zh) * | 2024-10-31 | 2026-06-30 | 无锡诺宇医药科技有限公司 | 成纤维细胞活化蛋白靶向的放射性药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100844593B1 (ko) | 2004-03-09 | 2008-07-07 | 내셔날 헬스 리서치 인스티튜트 | 피롤리딘 화합물 |
| WO2013107820A1 (en) | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| WO2015073678A1 (en) * | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| JP7162592B2 (ja) | 2016-12-14 | 2022-10-28 | パーデュー・リサーチ・ファウンデイション | 線維芽細胞活性化タンパク質（ｆａｐ）標的イメージングおよび治療 |
| JP2021500373A (ja) | 2017-10-23 | 2021-01-07 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 線維芽細胞活性化タンパク質α（ＦＡＰ−α）を標的とする撮像剤および放射線療法用薬剤 |
| AU2018386298B2 (en) | 2017-12-15 | 2023-09-07 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| PH12020551205A1 (en) * | 2018-02-06 | 2021-04-19 | Univ Heidelberg | Fap inhibitors |
| WO2019154859A1 (en) | 2018-02-06 | 2019-08-15 | Universität Heidelberg | Fap inhibitor |
| KR20220154111A (ko) * | 2020-02-12 | 2022-11-21 | 필로켐 아게 | 표적 전달 적용들을 위한 섬유아세포 활성화 단백질 리간드들 |
-
2022
- 2022-10-04 JP JP2024520693A patent/JP2024536362A/ja active Pending
- 2022-10-04 AU AU2022358921A patent/AU2022358921A1/en active Pending
- 2022-10-04 WO PCT/EP2022/077598 patent/WO2023057457A1/en not_active Ceased
- 2022-10-04 KR KR1020247015053A patent/KR20240093543A/ko active Pending
- 2022-10-04 MX MX2024004077A patent/MX2024004077A/es unknown
- 2022-10-04 IL IL311694A patent/IL311694A/en unknown
- 2022-10-04 EP EP22801357.9A patent/EP4412996A1/en active Pending
- 2022-10-04 CA CA3234394A patent/CA3234394A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311694A (en) | 2024-05-01 |
| EP4412996A1 (en) | 2024-08-14 |
| KR20240093543A (ko) | 2024-06-24 |
| WO2023057457A1 (en) | 2023-04-13 |
| JP2024536362A (ja) | 2024-10-04 |
| CA3234394A1 (en) | 2023-04-13 |
| AU2022358921A1 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xu et al. | A phase III multicenter randomized clinical trial of 60 Gy versus 50 Gy radiation dose in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma | |
| Deng et al. | The application of nanotechnology in immune checkpoint blockade for cancer treatment | |
| Grams et al. | Minibeam radiation therapy treatment (MBRT): commissioning and first clinical implementation | |
| Stone et al. | Effects of radiation on normal tissue: consequences and mechanisms | |
| Kong et al. | Reirradiation of locally recurrent nasopharyngeal cancer: history, advances, and promises for the future | |
| CL2021002267A1 (es) | Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945) | |
| Darakchiev et al. | Safety and efficacy of permanent iodine-125 seed implants and carmustine wafers in patients with recurrent glioblastoma multiforme | |
| Baker | Harnessing cerium oxide nanoparticles to protect normal tissue from radiation damage | |
| Brown-Glaberman et al. | Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors | |
| Fujiwara et al. | Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2–IVA cervical cancer and its clinical prognostic factors | |
| ZA202403256B (en) | Dual-targeting compound for fibroblast activation protein (fap) and integrin αvβ3, preparation method therefor and use thereof | |
| WO2020132560A3 (en) | Compositions and methods for cancer therapy | |
| MX2025008524A (es) | Métodos y composiciones para la terapia combinada | |
| MX2024015058A (es) | Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer | |
| Onishi et al. | Efficacy of hepatic arterial infusion chemotherapy in combination with irradiation for advanced hepatocellular carcinoma with portal vein invasion | |
| Koukourakis et al. | Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy | |
| WO2021127556A8 (en) | Methods for treating cancer comprising low dose radiation | |
| EP3003400B1 (en) | Treatment of immune, inflammatory and degenerative arthritides with tin-117m | |
| Sugimoto et al. | Efficacy of concurrent superselective intra-arterial chemotherapy and radiotherapy for late-stage squamous cell carcinoma of the temporal bone. | |
| Eblan et al. | Hypofractionation for breast cancer: lessons learned from our neighbors to the north and across the pond | |
| WO2025186743A8 (en) | Combinations for treating cancer in standard of care and/or profibrotic chemotherapeutic agent-naive patients using tumor treating fields and chemotherapeutic agents | |
| CA2726050A1 (en) | Achievement of high therapeutic index through molecular imaging guided targeted drug treatment | |
| MX2019010732A (es) | Uso de moduladores de receptor de glucocorticoide en el tratamiento de tumores secretores de catecolamina. | |
| of Lung et al. | Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2019 version) | |
| Nakai et al. | Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer |